Major Biotech Short Interest Continues to Be Mixed

Health and Healthcare

Published: February 10, 2016 8:40 am

Last Updated: January 13, 2020 1:23 pm

The short interest data are out for the January 29 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break them. A single failed clinical trial can mean disaster for a stock. 24/7 Wall St. has reviewed the top biotech companies, without focusing on speculative companies.

The January 29 short interest data have been compared with the previous report, and short interest was mixed in most of these selected stocks for this settlement date.

Amgen Inc. (NASDAQ: AMGN) saw its short interest rise to 10.41 million shares from the previous level of 9.03 million. Shares closed most recently at $143.16, in a 52-week trading range of $130.09 to $181.81.

Biogen Inc. (NASDAQ: BIIB) had its short interest decrease slightly to 2.76 million from the previous level of 2.85 million. Shares closed Tuesday at $249.99, within a 52-week range of $243.85 to $480.18.

Celgene Corp. (NASDAQ: CELG) short interest for this settlement date increased to 10.50 million shares from the previous 9.06 million. Shares of Celgene closed most recently at $100.50, in a 52-week range of $92.98 to $140.72.

ALSO READ: The 6 Most Shorted Nasdaq Stocks: Short Sellers in Retreat

Gilead Sciences Inc. (NASDAQ: GILD) saw its short interest fall to 21.37 million shares from 23.16 million in the previous period. Shares closed Tuesday at $87.25, in a 52-week trading range of $81.89 to $123.37.

MannKind Corp. (NASDAQ: MNKD) saw its short interest increase to 124.41 million shares. The previous reading was 123.89 million. Shares closed most recently at $0.97, in a 52-week trading range of $0.64 to $7.88.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) short interest decreased to 5.47 million, compared to the
previous level of 5.65 million. Shares closed most recently at $136.46, in a 52-week range of $130.51 to $208.88.

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.